Effects of Ischemia Reperfusion Injury on Outcomes in Kidney Transplantation; Public Workshop
September 8 – 10, 2011
Silver Spring, MDUS
The Food and Drug Administration (FDA) is announcing a public workshop to discuss the effects of ischemia/reperfusion injury (IRI) on outcomes in kidney transplantation. This public workshop is intended to obtain information from health care providers, academic, and industry on various aspects of the pathophysiology, clinical management, and outcomes following IRI. The meeting will include a discussion of animal models, devices, and clinical trial design. The input from this public workshop will help in developing topics for further discussion and may serve to inform recommendations on clinical trial design for products for the mitigation of IRI and/or for the prophylaxis and/or treatment of delayed graft function (DGF) and related conditions in kidney transplant recipients.
Registration is free for the public workshop. Interested parties are encouraged to register early because space is limited. Seating will be available on a first-come-first-served basis. To register electronically, email registration information (including name, title, firm name, address, telephone and fax number) to: IRIworkshop@fda.hhs.gov. Persons without access to the internet can call Christine Mose at: 301-796-1300 or Romou Mauer at: 301-796-1600 to register.
For further information, please visit: http://www.fda.gov/Drugs/NewsEvents/ucm263860.htm